Hims & Hers Health, Inc. ( HIMS ) announced the acquisition of a California-based peptide facility to enhance its domestic supply chain and meet rising demand for personalized medications. The deal’s terms were not disclosed.

The acquisition reinforces Hims & Hers’ U.S.-based supply chain, providing greater control over costs, availability, quality, and safety while further integrating its operations for long-term efficiency.

The new facility also enhances the company’s potential for peptide innovation in key areas such as preventive health, metabolic optimization, cognitive performance, recovery science, and biological resistance, aligning with the growing demand for personalized treatments.

“We’re building our supply chain to enable more Americans to access care, including personalized treatments designed around their needs. This acquisition is a reflection of our commitment to those goals and our ongoing investment in the customer from start to finish,” said Melissa Baird, COO of Hims & Hers.

Recently, Hims & Hers acquired at-home lab testing facility Trybe Labs, enabling blood draws and whole-body testing. This expansion enhances personalized treatments, supports early disease detection, and accelerates the company’s entry into new clinical categories.

In another development, the FDA announced that the semaglutide injection shortage has been resolved as of Feb. 21.

Last year, Hims & Hers Health ( HIMS ) launched a GLP-1 Supply Tracker to help individuals report access issues and advocate for improved availability of branded GLP-1 medications. The tool serves as a data collection and advocacy resource, providing the FDA with insights into supporting better healthcare access.

Today, the FDA confirmed with the drug’s manufacturer that their stated product availability and manufacturing capacity can meet the present and projected national demand.

Price Action: HIMS shares are trading lower by 17.2% at $55.01 on the last check Friday.